Developer docs
API playgroundTry for free, no card

Search company profiles

Mars Bioimaging

Full company profile

uuid000993l

Namestring
Mars Bioimaging
Legal namestring
MARS Bioimaging Limited
Company typeenum
Private
Founded yearint
2007
Descriptiontext

MARS Bioimaging Ltd is a Christchurch, New Zealand–based medical imaging company founded in 2007 to commercialize spectral photon-counting CT technology originating from CERN's particle physics research. The company holds an exclusive licence from CERN to deploy Medipix3 photon-counting detector technology for medical imaging in point-of-care settings, developed through the Medipix3 Collaboration with the University of Canterbury. Its technology captures and differentiates multiple X-ray energy levels in a single scan, enabling identification and quantification of intrinsic materials (bone, soft tissue) and extrinsic materials (contrast agents, nanoparticles). The flagship product, the MARS Bioimaging Extremity Scanner System, is a portable photon-counting CT scanner that received U.S. FDA 510(k) clearance in March 2026 for upper extremity imaging in community and point-of-care settings, including clinical offices, sports medicine clinics, and ambulatory service units. A secondary product, the Mars Microlab, extends the portable CT platform to broader point-of-care applications.

The company operates a hardware-sales revenue model, selling photon-counting CT scanner systems through direct enterprise sales to clinical and research customers. Named customers include Hospital for Special Surgery (HSS) in New York, a development partner and the world's leading academic musculoskeletal center, and Bracco Imaging in Italy, a research buyer using the system for contrast agent and AI-enhanced diagnostic imaging research. Revenue mechanics are quote-based and pricing is not publicly disclosed. GTM combines enterprise field sales (clinical offices, sports medicine, ambulatory units) with channel-style sales to research institutions for contrast agent and AI research applications.

Mars Bioimaging employs 20 people in Christchurch and plans to add five more over the next six months. It completed a $15 million oversubscribed Series A in 2024 with backing from New Zealand, Singapore, and Switzerland investors, with Pacific Channel as a strategic board-level investor. The Series A funded FDA pursuit and commercial expansion into the United States (the largest CT market), India, and continued New Zealand operations. Physical production is handled by local Christchurch engineering firm Argus ManuTech, and leadership is anchored by Group CEO Dr. Ojas Mahapatra, Co-Founder/CTO Prof. Anthony Butler, and Chairman Christopher Stoelhorst.

Short descriptiontext

MARS Bioimaging is a New Zealand medtech company that develops portable photon-counting CT scanners using CERN-licensed Medipix3 detector technology. It sells the FDA-cleared MARS Extremity Scanner System to clinical offices, sports medicine clinics, and research institutions for point-of-care musculoskeletal imaging.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChristchurch, New Zealand
HQ citystring
Christchurch
HQ countrystring
New Zealand
HQ regionstring
Oceania
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
photon-counting CT scanners, medical imaging equipment, spectral CT imaging, musculoskeletal imaging systems, portable point-of-care CT
Industry2 codes
PRIMARYHLAHABAB
Computed Tomography (CT) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code3 codes
  • Irradiation Apparatus Manufacturing334517
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Equipment
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Photon-Counting CT Scanner Sales
TypeHardware Sales
Description

Sale of portable photon-counting CT scanner systems to clinical and research institutions. The company sells its MARS Extremity Scanner System and mobile scanners for research applications.

scoop.co.nz
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MARS Bioimaging designs, manufactures, and sells portable photon-counting CT scanners based on Medipix3 detector technology licensed from CERN. The company's flagship MARS Extremity Scanner System is a compact spectral CT system that delivers high-resolution 3D X-ray images with material differentiation (bone, soft tissue, contrast agents, implants) in community and point-of-care clinical settings, and the Mars Microlab CT Scanner offers a portable unit for advanced imaging outside hospital radiology departments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • FDA 510(k) clearance achieved March 2026, enabling commercial rollout in the United States as the world's largest CT market
Product overview1 text field

MARS Bioimaging offers a portfolio of portable photon-counting CT scanners based on Medipix3 detector technology licensed from CERN. The core product is the FDA-cleared MARS Bioimaging Extremity Scanner System, a compact spectral CT system for upper extremity imaging designed for point-of-care and community-based settings. The Mars Microlab CT Scanner is a portable unit that brings diagnostics closer to patients with exceptional spatial resolution and low radiation dose. Both products leverage spectral photon-counting technology to deliver high-resolution 3D color images with material decomposition capabilities.

Product and service2 records
1MARS Bioimaging Extremity Scanner System
CategoryMedical Imaging Hardware
Description

FDA-cleared portable photon-counting CT scanner designed for upper extremity imaging in community and point-of-care settings. Delivers high-resolution 3D X-ray images with clear material differentiation, visualizing soft tissue, bone, blood vessels, and metallic implants. Features spectral imaging and material decomposition capabilities at lower radiation dose.

2Mars Microlab CT Scanner
CategoryMedical Imaging Hardware
Description

Portable CT scanner offering greater portability compared to traditional CT scanners that can weigh up to three tonnes. Enables advanced imaging at point-of-care and in community-based settings with exceptional spatial resolution and low radiation dose.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

Bracco Imaging S.p.A. purchased a mobile photon-counting CT scanner from MARS Bioimaging to support its contrast agent and artificial intelligence research at its research center in Colleretto Giacosa, Italy. The MARS Bioimaging Extremity Scanner System will be used to investigate how AI and advanced imaging can enhance diagnostic outcomes through spectral imaging and material decomposition capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

HSS in New York City, the world's leading academic medical center focused on musculoskeletal health, collaborated with MARS Bioimaging on the portable photon-counting CT scanner for upper extremities. The collaboration supported the development of imaging technology aimed at enhancing diagnostic patient care. HSS welcomed the FDA clearance news.

Strategic tierCoreTypeTechnology or Integration
Description

MARS Bioimaging holds the exclusive licence from CERN to commercialize Medipix3 photon-counting detector technology for medical imaging in point-of-care settings. The technology was developed originally through particle physics research at CERN by the Medipix3 Collaboration, which includes the University of Canterbury.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major CT and image-guided therapy vendor pursuing photon-counting detector research, competing broadly with MARS in diagnostic imaging while offering very different scale and distribution.

TypeDirect peer
Description

Specializes in point-of-care extremity CT systems (e.g., LineUP, pedCAT) for orthopedic imaging, directly competing with MARS in the same clinical workflow and target customer base of orthopedic and sports medicine clinics.

TypeBroad incumbent
Description

Offers a broad CT portfolio including advanced detector research and is a relevant incumbent competitor for both standard CT and emerging photon-counting applications.

TypeBroad incumbent
Description

Global CT leader with active photon-counting detector research and a broad installed base of hospital CT systems, representing both competitive overlap and a potential partner/acquirer given MARS's niche.

TypeBroad incumbent
Description

Focused on specialty imaging (women's health, skeletal health) including dedicated extremity and 3D imaging systems, comparable to MARS in specialty-imaging positioning but broader in scale.

TypeDirect peer
Description

Develops dedicated extremity and mammography imaging systems including orthopedic CT, competing with MARS for community-based orthopedic imaging volume.

TypeEmerging player
Description

Develops dedicated cone-beam CT systems for breast and specialty imaging, an emerging player with comparable technology philosophy (dedicated point-of-care CT) intersecting with MARS's niche.

TypeBroad incumbent
Description

Operates broadly in medical imaging with the NAEOTOM Alpha photon-counting CT, overlapping with MARS at the technology level (photon-counting) but serving a much wider CT portfolio and customer base.

TypeDirect peer
Description

Manufactures portable CT scanners such as BodyTom and CereTom for point-of-care imaging, directly overlapping with MARS's portable, point-of-care musculoskeletal and clinical-use positioning.

TypeBroad incumbent
Description

Provides portable and point-of-care X-ray and imaging solutions with an orthopedic/specialty focus, comparable to MARS in targeting community and ambulatory imaging workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mars Bioimaging

Medical Imaging Equipmentmarsbioimaging.com

MARS Bioimaging is a New Zealand medtech company that develops portable photon-counting CT scanners using CERN-licensed Medipix3 detector technology. It sells the FDA-cleared MARS Extremity Scanner System to clinical offices, sports medicine clinics, and research institutions for point-of-care musculoskeletal imaging.

What Mars Bioimaging does

MARS Bioimaging Ltd is a Christchurch, New Zealand–based medical imaging company founded in 2007 to commercialize spectral photon-counting CT technology originating from CERN's particle physics research. The company holds an exclusive licence from CERN to deploy Medipix3 photon-counting detector technology for medical imaging in point-of-care settings, developed through the Medipix3 Collaboration with the University of Canterbury. Its technology captures and differentiates multiple X-ray energy levels in a single scan, enabling identification and quantification of intrinsic materials (bone, soft tissue) and extrinsic materials (contrast agents, nanoparticles). The flagship product, the MARS Bioimaging Extremity Scanner System, is a portable photon-counting CT scanner that received U.S. FDA 510(k) clearance in March 2026 for upper extremity imaging in community and point-of-care settings, including clinical offices, sports medicine clinics, and ambulatory service units. A secondary product, the Mars Microlab, extends the portable CT platform to broader point-of-care applications.

The company operates a hardware-sales revenue model, selling photon-counting CT scanner systems through direct enterprise sales to clinical and research customers. Named customers include Hospital for Special Surgery (HSS) in New York, a development partner and the world's leading academic musculoskeletal center, and Bracco Imaging in Italy, a research buyer using the system for contrast agent and AI-enhanced diagnostic imaging research. Revenue mechanics are quote-based and pricing is not publicly disclosed. GTM combines enterprise field sales (clinical offices, sports medicine, ambulatory units) with channel-style sales to research institutions for contrast agent and AI research applications.

Mars Bioimaging employs 20 people in Christchurch and plans to add five more over the next six months. It completed a $15 million oversubscribed Series A in 2024 with backing from New Zealand, Singapore, and Switzerland investors, with Pacific Channel as a strategic board-level investor. The Series A funded FDA pursuit and commercial expansion into the United States (the largest CT market), India, and continued New Zealand operations. Physical production is handled by local Christchurch engineering firm Argus ManuTech, and leadership is anchored by Group CEO Dr. Ojas Mahapatra, Co-Founder/CTO Prof. Anthony Butler, and Chairman Christopher Stoelhorst.

Mars Bioimaging firmographics

Firmographics
Name
Mars Bioimaging
Legal name
MARS Bioimaging Limited
Website
https://marsbioimaging.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
MARS Bioimaging is a New Zealand medtech company that develops portable photon-counting CT scanners using CERN-licensed Medipix3 detector technology. It sells the FDA-cleared MARS Extremity Scanner System to clinical offices, sports medicine clinics, and research institutions for point-of-care musculoskeletal imaging.
Ownership category
akta.pro rank

Mars Bioimaging industry classification

Industry
Product category
Medical Imaging Equipment
NAICS
Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAB
Computed Tomography (CT) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAL
Portable, Mobile & Point-of-Care Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Photon-counting CT scanners
  • Medical imaging equipment
  • Spectral CT imaging
  • Musculoskeletal imaging systems
  • Portable point-of-care CT

Where Mars Bioimaging is headquartered

Location

Headquarters

HQ city
Christchurch
HQ country
New Zealand
HQ region
Oceania

Offices4 records

Markets served

Mars Bioimaging business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Photon-Counting CT Scanner Sales: Sale of portable photon-counting CT scanner systems to clinical and research institutions. The company sells its MARS Extremity Scanner System and mobile scanners for research applications.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Mars Bioimaging product offering

Product offering

Core offering

MARS Bioimaging designs, manufactures, and sells portable photon-counting CT scanners based on Medipix3 detector technology licensed from CERN. The company's flagship MARS Extremity Scanner System is a compact spectral CT system that delivers high-resolution 3D X-ray images with material differentiation (bone, soft tissue, contrast agents, implants) in community and point-of-care clinical settings, and the Mars Microlab CT Scanner offers a portable unit for advanced imaging outside hospital radiology departments.

Product overview

MARS Bioimaging offers a portfolio of portable photon-counting CT scanners based on Medipix3 detector technology licensed from CERN. The core product is the FDA-cleared MARS Bioimaging Extremity Scanner System, a compact spectral CT system for upper extremity imaging designed for point-of-care and community-based settings. The Mars Microlab CT Scanner is a portable unit that brings diagnostics closer to patients with exceptional spatial resolution and low radiation dose. Both products leverage spectral photon-counting technology to deliver high-resolution 3D color images with material decomposition capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • MARS Bioimaging Extremity Scanner System FDA-cleared portable photon-counting CT scanner designed for upper extremity imaging in community and point-of-care settings. Delivers high-resolution 3D X-ray images with clear material differentiation, visualizing soft tissue, bone, blood vessels, and metallic implants. Features spectral imaging and material decomposition capabilities at lower radiation dose.
  • Mars Microlab CT Scanner Portable CT scanner offering greater portability compared to traditional CT scanners that can weigh up to three tonnes. Enables advanced imaging at point-of-care and in community-based settings with exceptional spatial resolution and low radiation dose.

Quantifiable outcome

  • FDA 510(k) clearance achieved March 2026, enabling commercial rollout in the United States as the world's largest CT market

Companies that use Mars Bioimaging

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Mars Bioimaging technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Mars Bioimaging partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Bracco ImagingcoreStrategic or Co-development Partner · 20 May 2026Bracco Imaging S.p.A. purchased a mobile photon-counting CT scanner from MARS Bioimaging to support its contrast agent and artificial intelligence research at its research center in Colleretto Giacosa, Italy. The MARS Bioimaging Extremity Scanner System will be used to investigate how AI and advanced imaging can enhance diagnostic outcomes through spectral imaging and material decomposition capabilities.
  • Hospital for Special Surgery (HSS)coreStrategic or Co-development PartnerHSS in New York City, the world's leading academic medical center focused on musculoskeletal health, collaborated with MARS Bioimaging on the portable photon-counting CT scanner for upper extremities. The collaboration supported the development of imaging technology aimed at enhancing diagnostic patient care. HSS welcomed the FDA clearance news.
  • CERN / Medipix3 CollaborationcoreTechnology or IntegrationMARS Bioimaging holds the exclusive licence from CERN to commercialize Medipix3 photon-counting detector technology for medical imaging in point-of-care settings. The technology was developed originally through particle physics research at CERN by the Medipix3 Collaboration, which includes the University of Canterbury.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Mars Bioimaging competitors and assessment

Company assessment

Broad incumbents

  • Philips: Major CT and image-guided therapy vendor pursuing photon-counting detector research, competing broadly with MARS in diagnostic imaging while offering very different scale and distribution.
  • Canon Medical Systems: Offers a broad CT portfolio including advanced detector research and is a relevant incumbent competitor for both standard CT and emerging photon-counting applications.
  • GE HealthCare: Global CT leader with active photon-counting detector research and a broad installed base of hospital CT systems, representing both competitive overlap and a potential partner/acquirer given MARS's niche.
  • Hologic: Focused on specialty imaging (women's health, skeletal health) including dedicated extremity and 3D imaging systems, comparable to MARS in specialty-imaging positioning but broader in scale.
  • Siemens Healthineers: Operates broadly in medical imaging with the NAEOTOM Alpha photon-counting CT, overlapping with MARS at the technology level (photon-counting) but serving a much wider CT portfolio and customer base.
  • Carestream Health: Provides portable and point-of-care X-ray and imaging solutions with an orthopedic/specialty focus, comparable to MARS in targeting community and ambulatory imaging workflows.

Direct peers

  • Curvebeam: Specializes in point-of-care extremity CT systems (e.g., LineUP, pedCAT) for orthopedic imaging, directly competing with MARS in the same clinical workflow and target customer base of orthopedic and sports medicine clinics.
  • Planmed: Develops dedicated extremity and mammography imaging systems including orthopedic CT, competing with MARS for community-based orthopedic imaging volume.
  • Samsung Neurologica: Manufactures portable CT scanners such as BodyTom and CereTom for point-of-care imaging, directly overlapping with MARS's portable, point-of-care musculoskeletal and clinical-use positioning.

Emerging players

  • Koning Health: Develops dedicated cone-beam CT systems for breast and specialty imaging, an emerging player with comparable technology philosophy (dedicated point-of-care CT) intersecting with MARS's niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mars Bioimaging social profiles

Digital presence

Mars Bioimaging compliance and trust

Trust signal

Compliance1 record

Mars Bioimaging financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mars Bioimaging leadership team

Management profile

Number of profiles

Profiles13 records

Mars Bioimaging funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mars Bioimaging M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mars Bioimaging

What does Mars Bioimaging do?

MARS Bioimaging designs, manufactures, and sells portable photon-counting CT scanners based on Medipix3 detector technology licensed from CERN. The company's flagship MARS Extremity Scanner System is a compact spectral CT system that delivers high-resolution 3D X-ray images with material differentiation (bone, soft tissue, contrast agents, implants) in community and point-of-care clinical settings, and the Mars Microlab CT Scanner offers a portable unit for advanced imaging outside hospital radiology departments.

Is Mars Bioimaging a public or private company?

Mars Bioimaging is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mars Bioimaging founded?

Mars Bioimaging was founded in 2007. It employs 11 to 50 people.

Where is Mars Bioimaging based?

Mars Bioimaging is headquartered in Christchurch, New Zealand, in the Oceania region.

How does Mars Bioimaging make money?

One revenue line is on record: photon-Counting CT Scanner Sales.

Who are Mars Bioimaging's main competitors?

Broad incumbents on record are Philips, Canon Medical Systems, GE HealthCare, Hologic, Siemens Healthineers and Carestream Health. Direct peers are Curvebeam, Planmed and Samsung Neurologica. Koning Health is listed as an emerging player.

Does Mars Bioimaging have an API?

No public API is recorded for Mars Bioimaging.

What industry is Mars Bioimaging in?

Mars Bioimaging's product category is Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAB, Computed Tomography (CT) Systems, with a secondary code of HLAHABAL, Portable, Mobile & Point-of-Care Imaging Systems. Its NAICS code is 334517 and its SIC code is 3844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScoopMARS Bioimaging Mobile Photon-Counting CT Scanner Selected For Contrast Agent And AI ResearchMARS Bioimaging sold a mobile photon-counting CT scanner to Bracco Imaging for research on contrast agents and AI. The scanner will be installed in Italy at Bracco's Research Center, supporting projects on spectral imaging and material decomposition. The sale marks a significant milestone for MARS Bioimaging's commercial development.Imaging Technology NewsFDA Approves Portable Photon-counting CT ScannerMARS Bioimaging received FDA 510(k) clearance for its portable photon-counting CT scanner designed for upper extremity imaging. This regulatory approval enables the New Zealand-based company to scale clinical adoption and commercial rollout of the device in the United States market. The technology, originally developed at CERN, is intended for use in community and point-of-care settings.Med-Tech InsightsMARS Bioimaging raises $15M for photon-counting CT scannersMARS Bioimaging, a New Zealand-based medical device company, has closed an oversubscribed 15 million NZD Series A A round led by Pacific Channel, raised in two tranches (7.6 million NZD initially and 7.4 million NZD in 2026). The funding will accelerate commercial adoption of the company's spectral photon-counting CT scanners across key markets including the United States, New Zealand, and select emerging markets such as India, while expanding sales and business development teams. New international investors include a Singapore-based med-sector company and a Swiss investor secured through New Zealand's Active Investor Plus programme.FinSMEsMARS Bioimaging Closes $15M Series A FundingMARS Bioimaging, a Christchurch-based medical device company specializing in spectral molecular imaging, closed a $15M Series A funding round led by Pacific Channel, structured as $7.6M in an initial close plus $7.4M in 2026. The company will use the proceeds to accelerate commercial adoption of its spectral photon-counting CT scanners, which provide 3D colour X-ray imaging with advanced material differentiation, across the United States, New Zealand and select emerging markets including India. The scanners leverage Medipix technology developed at CERN and can visualize soft tissue, bone, blood vessels and metallic implants without requiring X-ray contrast agents.ThepressChristchurch tech firm lands $15m, plans new local jobsChristchurch-based MARS Bioimaging has raised $15 million through a two-year fundraising round backed by New Zealand and overseas investors including new backers from Singapore and Switzerland. The company, which currently employs 20 people, plans to hire five additional staff in Christchurch over the next six months while using the funding to pursue FDA clearance and accelerate commercial expansion into the United States, New Zealand, and emerging markets such as India. MARS manufactures photon-counting CT scanners that produce high-resolution 3D color images, with physical production handled by local engineering company Argus ManuTech.HIT ConsultantMARS Bioimaging Secures $15M to Scale World’s First Portable Spectral CT ScannersMARS Bioimaging, a New Zealand-based medical imaging company, has secured $15 million in Series A funding led by Pacific Channel to scale commercial adoption of the world's first portable spectral photon-counting CT scanners. The technology delivers high-resolution 3D color images at point-of-care without requiring contrast agents, and the company plans to use the capital to expand sales and business development teams in New Zealand and the United States while targeting emerging markets including India. The funding round was raised in two tranches with $7.4 million already closed in 2026, attracting international investors including a Singapore-based med-sector firm and a Swiss investor.NZ HeraldChristchurch’s Mars Bioimaging raises $15m to take its portable colour X-ray machine to marketChristchurch-based medtech company Mars Bioimaging has raised $15 million in a Series A funding round to commercialize its portable Mars Microlab CT scanner. The round was oversubscribed, with the Government's new Golden Visa programme credited as a contributing factor to its success. CEO Ojas Mahapatra noted that traditional CT scanners can weigh up to three tonnes, anchoring them to hospitals, whereas the Mars Microlab offers greater portability for medical imaging.AuntMinnieMARS Bioimaging advances Series A round for color CT imaging systemMARS Bioimaging is advancing the final phase of its Series A investment round, targeting $10 million New Zealand dollars to support the clinical commercialization of its color CT imaging system. The funding, led by Pacific Channel, follows an initial close that raised $7.6 million and will be used for market development, talent acquisition, and supply chain scaling.LinkedInWe're thrilled to be investing in MARS Bioimaging Ltd's latest capital round.MARS Bioimaging Ltd raised a capital round, with investors citing the company's technology and stakeholder alignment. Kieran Jina highlighted that the technology works, has strong people, and simplifies FDA and reimbursement pathways, with a US customer to help.SpectrumlocalnewsLooking Forward as RPI Leads In­no­v­ative Cancer ResearchRensselaer Polytechnic Institute researchers, with Albany Medical College and MARS Bioimaging, developed 3D full-color x-ray imaging to study how cancer cells respond to drugs. The technology aims to reduce drug resistance by delivering medicines directly to all cancer cells in a tumor.